Galectin Therapeutics earnings were -$28.0M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest GALT earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$9.2M, up 81.1% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, GALT reported annual earnings of -$31.0M, with -34.4% growth.
Galectin Therapeutics Earnings Reports & History FAQ
What were Galectin Therapeutics's earnings last quarter?
On GALT's earnings call on Aug 13, 2026, Galectin Therapeutics (NASDAQ: GALT) reported Q2 2026 earnings per share (EPS) of -$0.14, up 16.67% year over year. Total GALT earnings for the quarter were -$9.18 million. In the same quarter last year, Galectin Therapeutics's earnings per share (EPS) was -$0.12.
Is Galectin Therapeutics profitable or losing money?
As of the last Galectin Therapeutics earnings report, Galectin Therapeutics is currently losing money. Galectin Therapeutics's net profit (also called net income) for the twelve months ending Jun 30, 2026 was -$27.84 million, a 30.98% decrease year over year.
What was GALT's earnings growth in the past year?
As of Galectin Therapeutics's earnings date in Aug 13, 2026, Galectin Therapeutics's earnings has grown year over year. GALT earnings in the past year totalled -$28.03 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.